Alvotech (NASDAQ:ALVOW – Get Free Report)’s share price fell 11.8% on Monday . The stock traded as low as $1.30 and last traded at $1.31. 7,791 shares were traded during trading, a decline of 1% from the average session volume of 7,899 shares. The stock had previously closed at $1.49.
Alvotech Price Performance
The company has a 50-day moving average price of $1.29 and a 200-day moving average price of $1.57.
About Alvotech
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass.
Featured Articles
- Five stocks we like better than Alvotech
- What is the FTSE 100 index?
- Eli Lilly Stock Soars on Trump Tariff Hopes and Pfizer Deal
- What is a Microcap Stock? Everything You Need to Know
- 3 Exceptional Stocks to Build Long-Term Wealth
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- Insider Sales Jump at Broadcom and CoreWeave: Red Flag Ahead?
Receive News & Ratings for Alvotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alvotech and related companies with MarketBeat.com's FREE daily email newsletter.